Skip Navigation



JAC Advance Access published online on February 12, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh126
© 2004 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
53/3/413    most recent
dkh126v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Buckwold, V. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buckwold, V. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 The British Society for Antimicrobial Chemotherapy

Leading article

Implications of finding synergic in vitro drug-drug interactions between interferon-{alpha} and ribavirin for the treatment of hepatitis C virus

Victor E. Buckwold 1 *

1 Infectious Disease Research Department, Southern Research Institute, Frederick, MD 21701, USA

* Corresponding author. E-mail: Buckwold{at}sri.org.

Abstract

Hepatitis C virus (HCV) infections are currently treated using a combination of interferon-{alpha} (IFN-{alpha}) and ribavirin (RBV). If IFN-{alpha} is utilized alone, the sustained virological response (SVR) rate is ~20%, whereas when RBV is used alone it does not lead to an SVR. However, when IFN-{alpha} and RBV are used together, the combination leads to an SVR rate of ~40%. This clinical synergy is thought to be due to the direct antiviral effects of RBV, or to indirect effects of RBV that stimulate the immune response. Evidence for either hypothesis is limited. Recently, we undertook an in vitro drug-drug combination analysis using surrogate model systems of HCV replication and found a reproducible synergy of antiviral effects between the two drugs at physiologically relevant drug concentrations. Our findings provide experimental support for the contention that the direct effects of these drugs’ antiviral activity are responsible for the clinical synergy observed in patients.

Keywords: interferon-{alpha}, combination analysis, HCV, ribavirin
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.